Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EB-FAPI in Advanced Cholopancreatic Tumors
NCT06081322Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-EB-FAPI in pancreatic cancer (PC) and cholangiocarcinoma (CCA) (3 arms), sponsored by Zhejiang University. Primary endpoints: Safety of treatment: hematotoxicity up to 2 years, Objective Response Rate up to 2 years and 2 more. Status: unknown.
02
Drugs
177Lu-DOTA-EB-FAPI
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06081322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081322.